ReviewCureus2025
Role of Targeted Therapy in the Management of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: A Single-Proportion Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease is challenging due to multifocality and the risk of renal failure from repeated surgery. Recent advances in targeted therapy directed at the hypoxia-inducible factor (HIF)-2α and vascular endothelial growth factor receptor (VEGFR) pathways offer new therapeutic options. This meta-analysis evaluated the overall response and toxicity of targeted therapy in VHL-associated RCC. A systematic literature search was conducted in PubMed, Embase, Cochrane, and Scopus databases from January 2000 to January 2024, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligible studies included clinical trials and retrospective analyses reporting the efficacy and adverse events of systemic targeted therapies in VHL-related RCC. Pooled response rates and confidence intervals (CI) were calculated using a random-effects model, with heterogeneity assessed by I² statistics. Five studies (188 RCC cases) met the inclusion criteria. The pooled overall response rate to targeted therapy was 42% (95% CI: 28-56). Subgroup analysis showed higher efficacy of HIF-2α inhibitors (belzutifan) compared to VEGFR inhibitors (62% vs. 44%; 95% CI: 49-74 and 30-59, respectively). Heterogeneity was moderate (I²=68%). Most adverse events were grades 1-2, with better tolerability in HIF-2α inhibitors. Targeted therapy focusing on the molecular pathogenesis of VHL-associated RCC provides meaningful disease control while preserving renal function. HIF-2α inhibitors demonstrate superior efficacy and lower toxicity compared with VEGFR-targeted agents, representing a promising non-surgical alternative for managing VHL-related RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.